Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection
11/04/2025 07:00 AM • Tonix Pharmaceuticals is collaborating with Massachusetts General Hospital to conduct a Phase 2 clinical trial of TNX-1500, a monoclonal antibody designed to prevent kidney transplant rejection with potentially reduced immunosuppressive drug side effects.
TNXP - Company is advancing innovative therapeutic approach for kidney transplant rejection, collaborating with a leading research hospital, and demonstrating progress in clinical development